Cargando…

The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial

OBJECTIVE: Hypotension is common in propofol anesthesia. Whether remimazolam could reduce intraoperative hypotension remains unknown. We therefore tested the primary hypothesis that remimazolam reduces the incidence of intraoperative hypotension compared with propofol in adult patients undergoing en...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yuwei, Gu, Wei, Zhao, Mingye, Zhang, Yunyun, Wu, Jingxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394743/
https://www.ncbi.nlm.nih.gov/pubmed/36004376
http://dx.doi.org/10.3389/fmed.2022.938940
_version_ 1784771544626495488
author Qiu, Yuwei
Gu, Wei
Zhao, Mingye
Zhang, Yunyun
Wu, Jingxiang
author_facet Qiu, Yuwei
Gu, Wei
Zhao, Mingye
Zhang, Yunyun
Wu, Jingxiang
author_sort Qiu, Yuwei
collection PubMed
description OBJECTIVE: Hypotension is common in propofol anesthesia. Whether remimazolam could reduce intraoperative hypotension remains unknown. We therefore tested the primary hypothesis that remimazolam reduces the incidence of intraoperative hypotension compared with propofol in adult patients undergoing endoscopic submucosal dissection (ESD) surgery. MATERIALS AND METHODS: We conducted a prospective trial to compare patients who received either remimazolam or propofol bolus induction and thereafter intravenous infusion. The hemodynamic parameters were measured using CNAP(®) Monitor 500 system. Our primary analysis was to compare the incidence of hypotension defined as systolic blood pressure below 90 mmHg between remimazolam and propofol during the whole anesthesia period. RESULTS: The incidence of hypotension decreased by 50%, from 67.9% in propofol group to 32.1% in remimazolam group (p < 0.01). Patients received less amount of intraoperative phenylephrine in the remimazolam group than the propofol group (0 [0–40] μg vs. 80 [0–200] μg, p < 0.01). Time-weighted average and cumulative time of hypotension was lower in remimazolam group compared with propofol group (p < 0.05). Cardiac output continuously measured by CNAP was preserved much better in remimazolam group compared with propofol group (p = 0.01), while systemic vascular resistance did not differ between the groups. The median time from discontinuation until full alertness was 4 [3–11.8] min in the remimazolam group compared with 15 [12.0–19.8] min in the propofol group (p < 0.01). CONCLUSION: Remimazolam has better hemodynamic stability than propofol in adult patients undergoing ESD surgery. The benefits of remimazolam on hemodynamic stability and hypotension prevention may be partly contributed to its better preservation of cardiac output. CLINICAL TRIAL REGISTRATION: [http://www.chictr.org.cn/com/25/showproj.aspx?proj=61104], identifier [ChiCTR2000037975].
format Online
Article
Text
id pubmed-9394743
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93947432022-08-23 The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial Qiu, Yuwei Gu, Wei Zhao, Mingye Zhang, Yunyun Wu, Jingxiang Front Med (Lausanne) Medicine OBJECTIVE: Hypotension is common in propofol anesthesia. Whether remimazolam could reduce intraoperative hypotension remains unknown. We therefore tested the primary hypothesis that remimazolam reduces the incidence of intraoperative hypotension compared with propofol in adult patients undergoing endoscopic submucosal dissection (ESD) surgery. MATERIALS AND METHODS: We conducted a prospective trial to compare patients who received either remimazolam or propofol bolus induction and thereafter intravenous infusion. The hemodynamic parameters were measured using CNAP(®) Monitor 500 system. Our primary analysis was to compare the incidence of hypotension defined as systolic blood pressure below 90 mmHg between remimazolam and propofol during the whole anesthesia period. RESULTS: The incidence of hypotension decreased by 50%, from 67.9% in propofol group to 32.1% in remimazolam group (p < 0.01). Patients received less amount of intraoperative phenylephrine in the remimazolam group than the propofol group (0 [0–40] μg vs. 80 [0–200] μg, p < 0.01). Time-weighted average and cumulative time of hypotension was lower in remimazolam group compared with propofol group (p < 0.05). Cardiac output continuously measured by CNAP was preserved much better in remimazolam group compared with propofol group (p = 0.01), while systemic vascular resistance did not differ between the groups. The median time from discontinuation until full alertness was 4 [3–11.8] min in the remimazolam group compared with 15 [12.0–19.8] min in the propofol group (p < 0.01). CONCLUSION: Remimazolam has better hemodynamic stability than propofol in adult patients undergoing ESD surgery. The benefits of remimazolam on hemodynamic stability and hypotension prevention may be partly contributed to its better preservation of cardiac output. CLINICAL TRIAL REGISTRATION: [http://www.chictr.org.cn/com/25/showproj.aspx?proj=61104], identifier [ChiCTR2000037975]. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9394743/ /pubmed/36004376 http://dx.doi.org/10.3389/fmed.2022.938940 Text en Copyright © 2022 Qiu, Gu, Zhao, Zhang and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Qiu, Yuwei
Gu, Wei
Zhao, Mingye
Zhang, Yunyun
Wu, Jingxiang
The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title_full The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title_fullStr The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title_full_unstemmed The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title_short The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial
title_sort hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: a randomized trial
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394743/
https://www.ncbi.nlm.nih.gov/pubmed/36004376
http://dx.doi.org/10.3389/fmed.2022.938940
work_keys_str_mv AT qiuyuwei thehemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT guwei thehemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT zhaomingye thehemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT zhangyunyun thehemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT wujingxiang thehemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT qiuyuwei hemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT guwei hemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT zhaomingye hemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT zhangyunyun hemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial
AT wujingxiang hemodynamicstabilityofremimazolamcomparedwithpropofolinpatientsundergoingendoscopicsubmucosaldissectionarandomizedtrial